NeuroMetrix Inc (NURO)

2.02
0.02 0.98
NASDAQ : Health Care
Prev Close 2.04
Open 2.02
Day Low/High 2.02 / 2.03
52 Wk Low/High 1.35 / 4.96
Volume 1.37K
Avg Volume 44.40K
Exchange NASDAQ
Shares Outstanding 2.13M
Market Cap 4.25M
EPS -58.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NeuroMetrix Teams Up With U.S. Pain Foundation To Raise Awareness Of Chronic Pain

NeuroMetrix Teams Up With U.S. Pain Foundation To Raise Awareness Of Chronic Pain

In recognition of Pain Awareness Month this September, NeuroMetrix, Inc.

NeuroMetrix Announces Issuance Of New U.S. Patent For Automated Control Of Quell Therapy During Sleep

NeuroMetrix Announces Issuance Of New U.S. Patent For Automated Control Of Quell Therapy During Sleep

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.

NeuroMetrix Announces DPNCheck Distribution Agreement With Fukuda Denshi In Japan

NeuroMetrix Announces DPNCheck Distribution Agreement With Fukuda Denshi In Japan

NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck ® distribution in Japan.

NeuroMetrix Announces Shipment Of 100,000th Quell Device Since Launch In 2015

NeuroMetrix Announces Shipment Of 100,000th Quell Device Since Launch In 2015

NeuroMetrix, Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000 th Quell ® wearable device for treatment of chronic pain since commercial launch in mid-2015.

NeuroMetrix Reports Q2 2017 Financial Results

NeuroMetrix Reports Q2 2017 Financial Results

NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended June 30, 2017.

NeuroMetrix, Inc. Announces Date For 2017 Second Quarter Financial Results Conference Call

NeuroMetrix, Inc. Announces Date For 2017 Second Quarter Financial Results Conference Call

NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017.

NeuroMetrix Announces $7.0 Million Private Placement Of Preferred Stock

NeuroMetrix Announces $7.0 Million Private Placement Of Preferred Stock

NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000...

NeuroMetrix Reports Promotion Of Michael MacDonald To Senior Vice President And General Manager Of Diagnostics

NeuroMetrix Reports Promotion Of Michael MacDonald To Senior Vice President And General Manager Of Diagnostics

NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics.

NeuroMetrix Provides Update On Quell Health Cloud Including Promotion Of Dr. Xuan Kong To Chief Data Scientist

NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell ® Health Cloud.

NeuroMetrix Provides Update On Quell Wearable Pain Relief Clinical Program

NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell ® clinical program.

NeuroMetrix Announces Issuance Of New U.S. Patent For Quell Wearable Pain Relief Technology

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.

NeuroMetrix To Present At The Marcum Microcap Conference On June 16, 2017

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N.

NeuroMetrix Exhibits Quell Wearable Technology At 31st Annual SLEEP Meeting

NeuroMetrix, Inc. (Nasdaq: NURO) is showing  Quell®, its 100% drug-free Wearable Pain Relief Technology™ to sleep medicine professionals from around the world at SLEEP 2017, the 31st Annual...

NeuroMetrix To Present At The LD Micro Invitational Conference On June 6, 2017

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N.

NeuroMetrix Announces Issuance Of New U.S. Patent For Quell Wearable Pain Relief Technology

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.

NeuroMetrix Wins SBANE New England Innovation Award

NeuroMetrix, Inc. (Nasdaq:NURO) announced that it was the recipient of the Smaller Businesses Association of New England (SBANE) New England Innovation Award for the development and successful launch of Quell ®...

NeuroMetrix Launches The LivingQuell Blog, A New Platform For Exploring Perspectives On Chronic Pain

NeuroMetrix, Inc. (Nasdaq: NURO) today announced the launch of LivingQuell, a blog that will serve as an online resource for people affected by chronic pain - as well as the rapidly growing user base of the company's...

Preliminary Results From Clinical Study Evaluating Use Of Quell In Chemotherapy-Induced Peripheral Neuropathy To Be Presented At The American Pain Society Annual Meeting

NeuroMetrix, Inc. (Nasdaq: NURO) today reported that researchers from the University of Rochester School of Medicine and Dentistry will present a scientific poster titled "Wearable TENs band for chemotherapy-induced...

NeuroMetrix Announces One-for-Eight Reverse Split

NeuroMetrix, Inc. (NASDAQ:NURO) today announced a one-for-eight reverse split of its common stock effective as of Thursday, May 11, 2017.

NeuroMetrix Reports Substantial Expansion Of International Intellectual Property Assets For Quell Wearable Pain Relief Technology

NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Notices of Allowance has been issued for patents covering key technological features of the Company's Quell ® Wearable Pain Relief Technology™ by the European...

NeuroMetrix Hosts Inaugural Quell User Event

NeuroMetrix, Inc. (Nasdaq: NURO) held its first Quell ® Wearable Pain Relief Technology™ user event last Thursday, April 27.

NeuroMetrix Reports Q1 2017 Financial Results

NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2017.

NeuroMetrix Announces Availability Of Quell Wearable Pain Relief Technology At Bed Bath & Beyond

NeuroMetrix, Inc. (Nasdaq: NURO) today announced the availability of its flagship product, Quell®, at select number of Bed Bath & Beyond ® locations in North America.

NeuroMetrix Named A 50+ Innovation Leader

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it was selected as one of the healthcare industry's 50+ Innovation Leaders under an AARP initiative administered by MedCity News to recognize entrepreneurs, companies,...

NeuroMetrix, Inc. Announces Date For 2017 First Quarter Financial Results Conference Call

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2017 first quarter financial results before the opening of the market on Thursday, April 20, 2017.

NeuroMetrix Brings Quell Wearable For Pain Relief To American Academy Of Pain Medicine 33rd Annual Meeting

Coming together with thousands of leading clinicians who treat patients with chronic pain, NeuroMetrix, Inc.

NeuroMetrix Announces Availability Of Quell Wearable Pain Relief Technology At Best Buy

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell ® will be available in over 450 Best Buy ® stores nationwide beginning in mid-February and is now available for purchase on BestBuy.

NeuroMetrix Reports Q4 And Full Year 2016 Financial Results

NeuroMetrix Reports Q4 And Full Year 2016 Financial Results

NeuroMetrix, Inc. (Nasdaq: NURO, NUROW), today reported financial and business highlights for the quarter and year ended December 31, 2016.

TheStreet Quant Rating: E+ (Sell)